In this article (Cancer Discov 2017;7:391–9), which was published in the April 2017 issue of Cancer Discovery (1), an error in Fig. 2D was introduced by the compositor during the production of the paper. Specifically, Western blot data appearing for CAL-51 cells were duplicated to also appear for MDA-MB-231 cells. The online version of the article has been changed to show the correct data for MDA-MB-231 cells, and the amended figure is included below. The publisher regrets this error and apologizes to the authors and community for any inconvenience this may have caused.
Skip Nav Destination
Correction| July 05 2017
Correction: Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer
Online Issn: 2159-8290
Print Issn: 2159-8274
©2017 American Association for Cancer Research.
American Association for Cancer Research.
Cancer Discov (2017) 7 (7): 782.
- Views Icon Views
- Share Icon Share
- Search Site
Article Versions Icon
- Version of Record July 5 2017
- Proof June 12 2017
Correction: Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov 1 July 2017; 7 (7): 782. https://doi.org/10.1158/2159-8290.CD-17-0565
Download citation file:
Citing articles via